Fas functionality
| Marrow sample . | Control IgM (%) . | CH11 500 (%) . | Fas-Fc (%) . |
|---|---|---|---|
| Normal (n = 3) | 3.4 ± 0.5 | 3.7 ± 2 | 3.3 ± 0.6 |
| MDS (n = 6) | 11.5 ± 2.7 | 24.7 ± 8.13-150 | 5.5 ± 23-150 |
| Marrow sample . | Control IgM (%) . | CH11 500 (%) . | Fas-Fc (%) . |
|---|---|---|---|
| Normal (n = 3) | 3.4 ± 0.5 | 3.7 ± 2 | 3.3 ± 0.6 |
| MDS (n = 6) | 11.5 ± 2.7 | 24.7 ± 8.13-150 | 5.5 ± 23-150 |
Bone marrow samples from healthy donors and from patients with myelodysplastic syndromes (MDS) were cultured for 13 days in differentiation medium and then incubated with 500 ng/mL anti-Fas antibody (CH11) or control IgM for 20 hours or with 10 μg/mL Fas-Fc for 48 hours. Apoptosis was analyzed by counting annexin V-positive/propidium iodide-negative cells. Values are mean ± SD percentages. Statistical analysis compared CH11-treated or Fas-Fc-treated with IgM-treated MDS samples.
P < .05.